Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Phase 2 Completed 18 enrolled H. Lee Moffitt Cancer Center and Research Institute Chiron Corporation · collab National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Tretinoin may help cells that are involved in the body's immune response to work better. Interleukin-2 may stimulate the white blood cells to kill kidney cancer cells. Giving tretinoin together with interleukin-2 may kill more tumor cells. PURPOSE: This randomized phase II trial is studying how well giving three different doses of tretinoin together with interleukin-2 works in treating patients with stage IV kidney cancer.

Timeline

Start: 2004-08
Primary completion: 2006-06
Completion: 2013-07

Publications

Results Mirza N, Fishman M, Fricke I, Dunn M, Neuger AM, Frost TJ, Lush RM, Antonia S, Gabrilovich DI. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 2006 Sep 15;66(18):9299-307. doi: 10.1158/0008-5472.CAN-06-1690.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Tretinoin	Small molecule	—	—
Comparator	aldesleukin	Protein / enzyme biologic	—	Subcutaneous

Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer

Summary

Timeline

Publications

Drugs

Indications